CASI beat EPS expectations by 14.41%

CASI Pharmaceuticals, headquartered in Beijing, focuses on developing, commercializing, and acquiring therapeutics, particularly in hematology oncology, with products like EVOMELA in the U.S. and multiple FDA-approved generics in China. The company, which employs 224 people, went public on August 23, 2021, and operates globally with a pipeline including CNCT19, BI-1206, and other drugs addressing unmet medical needs.